JP2024538602A - インターロイキン-1活性の阻害剤としての新規の置換スルホニル尿素化合物 - Google Patents

インターロイキン-1活性の阻害剤としての新規の置換スルホニル尿素化合物 Download PDF

Info

Publication number
JP2024538602A
JP2024538602A JP2024519269A JP2024519269A JP2024538602A JP 2024538602 A JP2024538602 A JP 2024538602A JP 2024519269 A JP2024519269 A JP 2024519269A JP 2024519269 A JP2024519269 A JP 2024519269A JP 2024538602 A JP2024538602 A JP 2024538602A
Authority
JP
Japan
Prior art keywords
mmol
compound
mixture
occurrence
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538602A5 (https=
Inventor
ホンジャン ジャン
ピン チェン
フェイ ジャン
ペイフワ スン
Original Assignee
ビバ スター バイオサイエンシズ (スージョウ) カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビバ スター バイオサイエンシズ (スージョウ) カンパニー リミテッド filed Critical ビバ スター バイオサイエンシズ (スージョウ) カンパニー リミテッド
Publication of JP2024538602A publication Critical patent/JP2024538602A/ja
Publication of JP2024538602A5 publication Critical patent/JP2024538602A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024519269A 2021-09-29 2022-09-27 インターロイキン-1活性の阻害剤としての新規の置換スルホニル尿素化合物 Pending JP2024538602A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/121548 2021-09-29
CN2021121548 2021-09-29
PCT/US2022/077120 WO2023056264A1 (en) 2021-09-29 2022-09-27 Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity

Publications (2)

Publication Number Publication Date
JP2024538602A true JP2024538602A (ja) 2024-10-23
JP2024538602A5 JP2024538602A5 (https=) 2025-09-19

Family

ID=84329267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519269A Pending JP2024538602A (ja) 2021-09-29 2022-09-27 インターロイキン-1活性の阻害剤としての新規の置換スルホニル尿素化合物

Country Status (10)

Country Link
US (1) US20240400561A1 (https=)
EP (1) EP4408843A1 (https=)
JP (1) JP2024538602A (https=)
KR (1) KR20240089127A (https=)
CN (1) CN118251393A (https=)
AU (1) AU2022356377A1 (https=)
CA (1) CA3233673A1 (https=)
IL (1) IL311784A (https=)
MX (1) MX2024003948A (https=)
WO (1) WO2023056264A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11465992B2 (en) * 2017-07-07 2022-10-11 Inflazome Limited Sulfonamide carboxamide compounds
US11370776B2 (en) * 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
MX2020001776A (es) * 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
US11542255B2 (en) * 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3668861A1 (en) * 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
KR20200087759A (ko) * 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
GB201902327D0 (en) * 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds

Also Published As

Publication number Publication date
IL311784A (en) 2024-05-01
AU2022356377A1 (en) 2024-04-11
WO2023056264A1 (en) 2023-04-06
CN118251393A (zh) 2024-06-25
EP4408843A1 (en) 2024-08-07
US20240400561A1 (en) 2024-12-05
KR20240089127A (ko) 2024-06-20
MX2024003948A (es) 2024-06-28
CA3233673A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
JP2021107414A (ja) コロニー刺激因子−1受容体(csf−1r)阻害剤
JP2021500345A (ja) ムスカリン性アセチルコリン受容体m4のアンタゴニスト
CA3047336A1 (en) Chemical compounds as inhibitors of interleukin-1 activity
AU2022268977A1 (en) Compounds for targeting degradation of bruton's tyrosine kinase
KR20210019489A (ko) B형 간염 캡시드 조립 조절제
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
KR20150108390A (ko) 3-치환된 피라졸 및 dlk 억제제로서의 용도
CA2916468A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CA3180717A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
WO2022187266A1 (en) Novel substituted bicycli aza-heterocycles as sos1 inhibitors
JP2024517769A (ja) Lpaアンタゴニストとしての新規トリアゾール-ピリジン置換ピロリジニル及びテトラヒドロ-2h-ピラニル酢酸化合物
CA3241298A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CN119487006A (zh) 作为pge2受体拮抗剂的酰胺化合物
KR20230124608A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
AU2014234908A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors
KR20150056550A (ko) 키나제 억제제로서의 디히드로피롤리디노-피리미딘
JP2024538602A (ja) インターロイキン-1活性の阻害剤としての新規の置換スルホニル尿素化合物
US12338255B2 (en) Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
HK40107097A (zh) 作为白介素-1活性抑制剂的新型经取代的磺酰脲化合物
HK40116219A (zh) 新型双环经取代的磺酰脲化合物作为白介素-1活性的抑制剂
HK40102702A (zh) 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物
EA052733B1 (ru) Ингибиторы nlrp3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250910